Drugs
May 1, 2025
Sharmin Ghaznavi, Sarah G Richter
6 citations
Recent research has revived interest in psychedelics as treatments for depression. This review examines studies on psilocybin, ayahuasca, DMT, and 5-Me-O DMT for treatment-resistant and major depression. It discusses the potential to expand depression treatment options based on available data, while also highlighting the difficulties and limitations of psychedelic research that complicate assessment of that potential.
The primary care companion for CNS disorders
May 28, 2024
Sharmin Ghaznavi, Lourdes M Bernardez, Theodore A Stern
2 citations
The Psychiatric Consultation Service at Massachusetts General Hospital provides care for medical and surgical inpatients who also have psychiatric symptoms or conditions. During twice-weekly rounds, clinicians discuss diagnosis and management of these complex patients. These discussions are the basis for reports intended to help clinicians working at the intersection of medicine and psychiatry.
The American journal of psychiatry
January 1, 2025
Sharmin Ghaznavi, Jeremy N Ruskin, Stephen J Haggerty et al.
As psychedelics gain popularity as potential therapeutics, understanding their risks becomes as important as studying their benefits. This review examines known and potential harms, including enduring perceptual disturbances, triggering or worsening mania or psychosis, overuse and dependence, challenging experiences ("bad trips"), risks from increased neuroplasticity, and acute and cumulative cardiovascular effects. The authors call for continued research and monitoring, especially as these substances move into broader, less controlled use.